These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Donaldson EF; Harrington PR; O'Rear JJ; Naeger LK Hepatology; 2015 Jan; 61(1):56-65. PubMed ID: 25123381 [TBL] [Abstract][Full Text] [Related]
110. Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423. Keck ZY; Angus AG; Wang W; Lau P; Wang Y; Gatherer D; Patel AH; Foung SK PLoS Pathog; 2014 Aug; 10(8):e1004297. PubMed ID: 25122476 [TBL] [Abstract][Full Text] [Related]
111. Global distribution and prevalence of hepatitis C virus genotypes. Messina JP; Humphreys I; Flaxman A; Brown A; Cooke GS; Pybus OG; Barnes E Hepatology; 2015 Jan; 61(1):77-87. PubMed ID: 25069599 [TBL] [Abstract][Full Text] [Related]
113. Structural analysis of hepatitis C virus core-E1 signal peptide and requirements for cleavage of the genotype 3a signal sequence by signal peptide peptidase. Oehler V; Filipe A; Montserret R; da Costa D; Brown G; Penin F; McLauchlan J J Virol; 2012 Aug; 86(15):7818-28. PubMed ID: 22593157 [TBL] [Abstract][Full Text] [Related]
114. Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. Lacek K; Vercauteren K; Grzyb K; Naddeo M; Verhoye L; Słowikowski MP; Fafi-Kremer S; Patel AH; Baumert TF; Folgori A; Leroux-Roels G; Cortese R; Meuleman P; Nicosia A J Hepatol; 2012 Jul; 57(1):17-23. PubMed ID: 22414763 [TBL] [Abstract][Full Text] [Related]
115. Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry. Brown KS; Keogh MJ; Owsianka AM; Adair R; Patel AH; Arnold JN; Ball JK; Sim RB; Tarr AW; Hickling TP Protein Cell; 2010 Jul; 1(7):664-74. PubMed ID: 21203938 [TBL] [Abstract][Full Text] [Related]
116. Antibody bivalency improves antiviral efficacy by inhibiting virion release independently of Fc gamma receptors. Sahin M; Remy MM; Fallet B; Sommerstein R; Florova M; Langner A; Klausz K; Straub T; Kreutzfeldt M; Wagner I; Schmidt CT; Malinge P; Magistrelli G; Izui S; Pircher H; Verbeek JS; Merkler D; Peipp M; Pinschewer DD Cell Rep; 2022 Feb; 38(5):110303. PubMed ID: 35108544 [TBL] [Abstract][Full Text] [Related]
117. A Role for B Cells to Transmit Hepatitis C Virus Infection. Desombere I; Van Houtte F; Farhoudi A; Verhoye L; Buysschaert C; Gijbels Y; Couvent S; Swinnen W; Van Vlierberghe H; Elewaut A; Magri A; Stamataki Z; Meuleman P; McKeating JA; Leroux-Roels G Front Immunol; 2021; 12():775098. PubMed ID: 34975862 [TBL] [Abstract][Full Text] [Related]
118. Therapy Implications of Hepatitis C Virus Genetic Diversity. Martinez MA; Franco S Viruses; 2020 Dec; 13(1):. PubMed ID: 33383891 [TBL] [Abstract][Full Text] [Related]
119. Antibody Responses in Hepatitis C Infection. Law M Cold Spring Harb Perspect Med; 2021 Mar; 11(3):. PubMed ID: 32341067 [TBL] [Abstract][Full Text] [Related]
120. Clearance of hepatitis C virus is associated with early and potent but narrowly-directed, Envelope-specific antibodies. Walker MR; Leung P; Eltahla AA; Underwood A; Abayasingam A; Brasher NA; Li H; Wu BR; Maher L; Luciani F; Lloyd AR; Bull RA Sci Rep; 2019 Sep; 9(1):13300. PubMed ID: 31527718 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]